Last reviewed: July 1, 2026 Last updated: July 1, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Adam Gilden, MD, MSCE Medical Reviewer Moira Lawler Author Moira Lawler is a journalist who has spent more than a decade covering a range of health and lifestyle topics, including women's health, nutrition, fitness, mental health, and trav...
A fund may have temporary larger exposures to certain Underlying ETFs and under such circumstances, a funds return would be more greatly influenced by the returns of the Underlying ETFs with the larger exposures
Clinical context for the mechanism Phase 2 data published in 2023 reported mean body-weight reduction of up to 24.2% at 48 weeks in trial participants receiving the highest retatrutide dose tier
Why do labs matter so much